Skip to main content
SpringerLink
Log in

A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Fifty-three patients in an acute episode or exacerbation of psychosis were given thioridazine 200 or 400 mg daily for 2 weeks. Thioridazine and its active metabolites, mesoridazine and sulforidazine, were estimated in plasma by high performance liquid chromatography (HPLC) and radioreceptor assay (RRA). One week after institution of treatment, plasma concentrations of drug were stable in the morning 12 h after dosing. Drug levels varied widely between patients, but in all patients the relative level of thioridazine to mesoridazine was about one half and thioridazine to sulforidazine was about two fold. Estimates of neuroleptic activity by RRA and the weighted sum of thioridazine, mesoridazine and sulforidazine by HPLC were very similar. Plasma concentration of parent compound, metabolites, or the sum of active substances as estimated by HPLC or RRA, showed only modest correlations (r s=0.10–0.22, all NS) to the degree of improvement as measured by change on the Brief Psychiatric Rating Scale. Significant correlations were observed between plasma concentrations of drug and side effects, including dry mouth, blurred vision, or total rating on the Somatic Symptoms Scale. Even patients receiving the lowest dose and achieving the lowest plasma concentrations of drug showed considerable improvement. There was suggestive evidence that the patients achieving the highest plasma levels of drug did not have the best clinical outcome. These and similar observations from other studies suggest that currently used doses of neuroleptics may be excessive. Optimal drug effects as well as stronger relationships between dose, drug concentration, and clinical therapeutic effects might best be sought at doses below those in common use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alfredsson G, Härnyd C, Wiesel F-A (1985) Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients—relationship to drug concentrations. Psychopharmacology 85:8–13.

    Google Scholar 

  • Axelsson R (1977) On the serum concentrations and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine side-chain sulfone, in chronic psychotic patients. Curr Ther Res 21:587.

    Google Scholar 

  • Axelsson R, Martensson E (1976) Serum concentration and elimination from serum of thioridazine in psychiatric patients. Curr Ther Res 19:242–265.

    Google Scholar 

  • Axelsson R, Martensson E (1977) The concentration pattern of nonconjugated thioridazine metabolites in serum by thioridazine treatment and its relationship to physiological and clinical variables. Curr Ther Res 20:561–586.

    Google Scholar 

  • Baldessarini RJ, Katz B, Cotten P (1984) Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry 141:748–752.

    Google Scholar 

  • Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses. Arch Gen Psychiatry 45:79–91.

    Google Scholar 

  • Cohen BM (1983) The clinical utility of plasma neuroleptic levels. In: Stancer HC, Garfinkel PE, Rakoff VM (eds) Guidelines for the use of psychotropic drugs. Spectrum, Jamaica New York, pp 246–260.

    Google Scholar 

  • Cohen BM (1988) Neuroleptic drugs in the treatment of acute psychosis. In: Casey DE, Christensen AV (eds) Current trends in psychopharmacology. Springer, Berlin Heidelberg New York Tokyo, pp 47–61.

    Google Scholar 

  • Cohen BM, Lipinski JF (1981) Radioreceptor assays of blood levels of neuroleptics. In: Usdin E (ed) Neuroreceptors—basic and clinical aspects. Wiley, New York, pp 199–214.

    Google Scholar 

  • Cohen BM, Lipinski JF (1986) Treatment of acute psychosis with non-neuroleptic agents. Psychosomatics S27:7–16.

    Google Scholar 

  • Cohen BM, Herschel M, Aoba A (1979) Neuroleptic, antimuscarinic, and antiadrenergic activity of chlorpromazine, thioridazine, and their metabolites. Psychiatr Res, 1:199–208.

    Google Scholar 

  • Cohen BM, Herschel M, Miller EM, Baldessarini RJ (1980a) Radioreceptor assay of haloperidol tissue levels in the rat. Neuropharmacology 19:663–668.

    Google Scholar 

  • Cohen BM, Lipinski JF, Pope HG, Harris PQ, Altesman RI (1980b) Neuroleptic blood levels of patients on thioridazine and clinical improvement. Psychopharmacology 70:191–194.

    Google Scholar 

  • Cooper TB (1985) Neuroleptic drug monitoring and radioreceptor assays. J Clin Psychopharmacol 5:A15-A16.

    Google Scholar 

  • Creese I, Snyder SH (1977) A novel, simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270:180–182.

    Google Scholar 

  • Curry SH (1985) Commentary: the strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol 5:263–271.

    Google Scholar 

  • Davis JM, Erickson SE, Dekirmenjian H (1978) Plasma levels of antipsychotic drugs and clinical response. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 905–916.

    Google Scholar 

  • Delay J, Deniker P (1952) 38 Cas de psychoses traités par la cure prolongée et continue de 4560 R.P.C.R. Congrès. Méd Alién Neurol France 50:503–518.

    Google Scholar 

  • Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mauroidis ML (1984) Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 4:133–137.

    Google Scholar 

  • Gottschalk LA, DiNovo E, Biener R, Birch H, Syben M, Noble EP (1976) Plasma levels of mesoridazine and its metabolites and clinical response in acute schizophrenia after a single intramuscular drug dose. In: Gottschalk LA, Merlis S (eds) Pharmacokinetics of psychotic drugs. S.P. Medical Books, New York, pp 171–189.

    Google Scholar 

  • Hansen CB, Larsen N-E, Gulmann N (1982) Dose-response relationship of perphenazine in the treatment of acute psychoses. Psychopharmacology 27:112–115.

    Google Scholar 

  • Kane JM (1987) Treatment of schizophrenia. Schizophren Bull 13:133–156.

    Google Scholar 

  • Keepers GA, Clappison VJ, Casey DE (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113–1117.

    Google Scholar 

  • Kilts CD, Patrick KS, Breese GR, Mailman RB (1982) Simultaneous determination of thioridazine and its S-oxidized and N-demethylated metabolites using high-performance liquid chromatography on radially compressed silica. J Chromatogr 231:377–391.

    Google Scholar 

  • Linkowski P, Hubain P, von Frenckell R, Mendlewicz J (1984) Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatry Neurol Sci 234:231–236.

    Google Scholar 

  • Linnoila M, Rosenblatt JE, Jeste D, Skinner T, Potter WZ, Wyatt RJ (1982) Disparate serum thioridazine concentrations: liquid chromatography versus radioreceptor assay. Acta Pharmacol Toxicol 50:25–29.

    Google Scholar 

  • Mailman RB, Pierce FP, Crofton KM, Petitto J, De Haven DL, Kilts CO, Lewis MH (1984) Thioridazine and the neuroleptic radioreceptor assay. Biol Psychiatry 19:833–847.

    Google Scholar 

  • Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 81:354–356.

    Google Scholar 

  • May PRA, Van Putten T (1978) Plasma levels of chlorpromazine in schizophrenia: a critical review of the literature. Arch Gen Psychiatry 35:1081–1087.

    Google Scholar 

  • May PRA, Van Puten T, Jenden DJ (1981) Chlorpromazine levels and the outcome of treatment in schizophrenic patients. Arch Gen Psychiatry 38:202–207.

    Google Scholar 

  • McEvoy JP, Stiller RL, Farr R (1986) Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. J Clin Psychopharmacol 6:133–138.

    Google Scholar 

  • McKay G, Cooper JK, Gurnsey T, Midha KK (1985) A simple, sensitive, and simultaneous assay of thioridazine, sulforidazine, and mesoridazine in plasma by HPLC. Liq Chromatogr 3:256–279.

    Google Scholar 

  • Moulin MA, Davy JP, Debruyne D, Andersson JC, Bigot MC, Camsonne R, Poilpré E (1982) Serum levels monitoring and therapeutic effect of haloperidol in schizophrenic patients. Psychopharmacology 76:346–350.

    Google Scholar 

  • Pope HG, Lipinski JF, Cohen BM, Axelrod D (1980) Schizoaffective disorder: an invalid diagnosis? Am J Psychiatry 137:921–927.

    Google Scholar 

  • Sakalis G, Curry SH, Mould GP, Lader MH (1972) Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther 13:931–946.

    Google Scholar 

  • Sakurai Y, Takahashi R, Nakahara T, Ikenaga H (1980) Prediction of response to and actual outcome of chlorpromazine treatment in schizophrenic patients. Arch Gen Psychiatry 37:1057–1062.

    Google Scholar 

  • Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic dopamine receptors. Nature 261:717–719.

    Google Scholar 

  • Simpson GM, Yadalam K (1985) Blood levels of neuroleptics: the state of the art. J Clin Psychiatry 46(5:2):22–28.

    Google Scholar 

  • Smith RC, Baumgartner R, Burd A, Ravichandran GK, Mauldin M (1985) Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assay. Psychopharmacol Bull 21:52–58.

    Google Scholar 

  • Stoll AL, Baldessarini RJ, Cohen BM, Finklestein SP (1984) Assay of plasma thioridazine and metabolites by high performance liquid chromatography with amperometric detection. J Chromatogr Biomed Appl 307:457–463.

    Google Scholar 

  • Van Putten T, Marder SR, Mintz J (1987) The therapeutic index of haloperidol in newly admitted schizophrenic patients. Psychopharmacol Bull 23:201–205.

    Google Scholar 

  • Vanderheeren FAJ, Muusze RG (1977) Plasma levels and half-lives of thioridazine and some of its metabolites. Eur J Clin Pharmacol 11:135–140.

    Google Scholar 

  • Volavka J, Cooper TB (1987) Review of haloperidol blood level and clinical response: looking through the window. J Clin Psychopharmacol 7:25–30.

    Google Scholar 

  • Wahba M, Donlon PT, Meadow A (1981) Cognitive changes in acute schizophrenia with brief neuroleptic threatment. Am J Psychiatry 138:1307–1310.

    Google Scholar 

  • Widerlov J-E, Häggström CD, Kilts CD, Andersson U, Breese GR, Mailman RB (1982) Serum concentrations of thioridazine, its major metabolites and serum neuroleptic-like activities in schizophrenics with and without tardive dyskinesia. Acta Psychiatr Scand 66:294–305.

    Google Scholar 

  • Wode-Helgodt B, Borg S, Fryo B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 58:149–173.

    Google Scholar 

  • Yesavage JA, Holman CA, Cohn R, Lombozo L (1983) Correlation of initial thiothixene serum levels and clinical response. Arch Gen Psychiatry 40:301–304.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. McLean Hospital, 115 Mill Street, 02178, Belmont, MA, USA

    Bruce M. Cohen, Joseph F. Lipinski & Christine Waternaux

  2. Harvard Medical School, 02115, Boston, MA, USA

    Bruce M. Cohen & Joseph F. Lipinski

  3. Harvard School of Public Health, 02115, Boston, MA, USA

    Christine Waternaux

Authors
  1. Bruce M. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph F. Lipinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Waternaux
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, B.M., Lipinski, J.F. & Waternaux, C. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacology 97, 481–488 (1989). https://doi.org/10.1007/BF00439552

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00439552

Key words

Search

Navigation